Previous Article |
Table of Contents
| Next Article
* Columbia Genome Center, Columbia University College of Physicians
and Surgeons, New York, NY 10032; § Department of Pathology,
Columbia University College of Physicians and Surgeons, New York, NY
10032; and ¶ Division of Epidemiology, School of Public Health,
Columbia University, New York, NY 10032
Contributed by Isidore S. Edelman, October 7, 1996
The genome of the Kaposi sarcoma-associated herpesvirus (KSHV or
HHV8) was mapped with cosmid and phage genomic libraries from the BC-1
cell line. Its nucleotide sequence was determined except for a 3-kb
region at the right end of the genome that was refractory to cloning.
The BC-1 KSHV genome consists of a 140.5-kb-long unique coding region
flanked by multiple G+C-rich 801-bp terminal repeat sequences. A
genomic duplication that apparently arose in the parental tumor is
present in this cell culture-derived strain. At least 81 ORFs,
including 66 with homology to herpesvirus saimiri ORFs, and 5 internal
repeat regions are present in the long unique region. The virus encodes
homologs to complement-binding proteins, three cytokines (two
macrophage inflammatory proteins and interleukin 6), dihydrofolate
reductase, bcl-2, interferon regulatory factors,
interleukin 8 receptor, neural cell adhesion molecule-like adhesin, and
a D-type cyclin, as well as viral structural and metabolic proteins.
Terminal repeat analysis of virus DNA from a KS lesion suggests a
monoclonal expansion of KSHV in the KS tumor.
Kaposi sarcoma (KS) is a vascular tumor of mixed cellular
composition (1). Its histology and relatively benign course in persons
without severe immunosuppression has led to suggestions that KS tumor
cell proliferation is cytokine-induced (2). Epidemiologic studies
indicate the tumor is under strict immunologic control and is likely to
be caused by a sexually transmitted infectious agent other than HIV
(3). KS-associated herpesvirus (KSHV) was discovered in an
AIDS-KS lesion by representational difference analysis and
shown to be present in almost all AIDS-KS lesions (4). These findings
have been confirmed and extended to nearly all KS lesions examined from
the various epidemiologic classes of KS (5-9). KSHV is the eighth
presumed human herpesvirus (HHV8) identified to date.
The virus was initially identified from two herpesvirus DNA fragments,
KS330Bam and KS631Bam (4). Subsequent sequencing of a 21-kb AIDS-KS
genomic library fragment (KS5) hybridizing to KS330Bam demonstrated
that KSHV is a gamma-herpesvirus related to herpesvirus saimiri (HVS)
belonging to the genus Rhadinovirus (10). Colinear homology
(synteny) of genes in this region is maintained between KSHV and HVS,
as well as Epstein-Barr virus (EBV) and equine herpesvirus 2. A 12-kb
region (bacteriophage clones L54 and SGL-1) containing the KS631Bam
sequence includes cyclin D and interleukin 8 receptor type a (IL-8Ra)
homologs unique to rhadinoviruses (11).
KSHV is not readily transmitted to uninfected cell lines (10), but it
is present in a rare B-cell primary effusion (body cavity-based)
lymphoma (PEL) frequently associated with KS (12). BC-1 is a PEL cell
line containing a high KSHV genome copy number and is coinfected with
EBV (13). The KSHV genome form in BC-1 and its parental tumor
comigrates with 270-kb linear markers on pulsed field gel
electrophoresis (10). However, the genome size based on encapsidated
DNA from an EBV-negative cell line (14) is estimated to be 165 kb (15).
Estimates from KS lesions indicate a genome size larger than that of
EBV (172 kb) (16).
To determine the genomic sequence of KSHV and identify novel virus
genes, we mapped contiguous, overlapping virus DNA inserts from BC-1
genomic libraries. With the exception of a small, unclonable repeat
region at its right end, the genome was sequenced to high redundancy
allowing definition of the viral genome structure and identification of
genes that may play a role in KSHV-related pathogenesis.
BC-1, HBL-6, and BCP-1 cells
were maintained in RPMI 1640 medium with 20% fetal calf serum (10, 13,
17). DNA (18) from BC-1 cells was commercially cloned into either
Lambda FIXII or S-Cos1 vectors (Stratagene). Phage and cosmid libraries
were screened by standard methods (19, 20).
Initial library screening was performed using the KS330Bam and KS631Bam
representational difference analysis fragments (4). Overlapping clones
were sequentially identified using probes synthesized from the ends of
previously identified clones (see Fig. 1) (21, 22). The map was
considered circularly permuted by the presence of multiple, identical
terminal repeat (TR) units in cosmids Z2 and Z6. Each candidate phage
or cosmid was confirmed by tertiary screening.
Lambda and
cosmid DNA were purified by standard methods (18). Shotgun sequencing
(23, 24) was performed on sonicated DNA. A 1-4 kb fraction was
subcloned into M13 mp19 (New England Biolabs) and propagated in
XL1-Blue cells (Stratagene) (18). M13 phages were positively screened
by using insert DNA from the phage or cosmid, and negatively screened
with vector arm DNA or adjacent genome inserts.
Automated dideoxy cycle sequencing was performed with M13 ( Sequence
data were edited using FACTURA (Applied Biosystems) and
assembled into contiguous sequences using electropherograms with
AutoAssembler (Applied Biosystems) and into larger assemblies with
ASSEMBLYLIGN (IBI-Kodak). Base positions not clearly
resolved by multiple sequencing attempts (less than 10 bases in total) were assigned the majority base pair designation. The entire sequence (in 1- to 5-kb fragments) and all predicted ORFs were analyzed by using
BLASTX, BLASTP, and BLASTN (25).
The sequence was further analyzed using MOTIFS (10),
REPEAT, and BESTFIT (Genetics Computer Group,
Madison, WI), and MACVECTOR (IBI).
All ORFs with homologies to
HVS were identified. These and other potential ORFs having >100 amino
acids were found using MACVECTOR. ORFs not homologous to
HVS ORFs were included in the map (see Fig. 1) based on homology to
known genes, optimum initiation codon context (26), size, and position.
Conservative selections were made to minimize spurious assignments;
this underestimates the number of true reading frames. KSHV ORF
nomenclature is based on HVS homologies; KSHV ORFs not homologous to
HVS genes are numbered in consecutive order with a K prefix. ORFs with
sequence but not positional homology to HVS ORFs were assigned the HVS
ORF number (e.g., ORF2). As new ORFs are identified, we suggest they be
designated by decimal notation. The standard map orientation (see Fig.
1) of the KSHV genome is the same as for HVS (27) and equine
herpesvirus 2 (28), and reversed relative to the EBV standard map (29).
Complete genome
mapping was achieved with seven lambda and three cosmid clones (Fig.
1). The structure of the BC-1 KSHV genome is
similar to HVS in having a long unique region (LUR) flanked by TR
units. The
The genome sequence abutting the right terminal repeat region is
incomplete due to a 3-kb region in the Z2 cosmid insert that could not
be cloned into sequencing vectors. Partial sequence information from
primer walking indicates that this region contains stretches of 16-bp
A+G-rich imperfect direct repeats interspersed with at least one
stretch of 16-bp C+T-rich imperfect direct repeats. These may form a
larger inverted repeat that could have contributed to our difficulty in
subcloning this region. Greater than 12-fold average sequence
redundancy was achieved for the entire LUR with complete bidirectional
coverage by at least four overlapping reads except in the unclonable
region.
The BC-1 TR region was examined by Southern blot analysis because
sequencing of the entire region is not possible due to its repeat
structure. BC-1, BCP-1 (an EBV-negative, KSHV infected cell line), and
KS lesion DNAs have an intense Based on the EBV replication model used in clonality studies (31), the
polymorphic BCP-1 laddering pattern may reflect lytic virus replication
and superinfection (Fig. 2C). The EBV laddering pattern
occurs when TR units are deleted or duplicated during lytic replication
and is a stochastic process for each infected cell (31). No laddering
is present for BC-1 which is under tight latent KSHV replication
control (10). KS lesion DNA also shows a single hybridizing band
suggesting that virus in KS tumor cells may be of monoclonal origin. A
monoclonal or oligoclonal banding pattern is present in most KS lesions
examined (data not shown).
The KSHV genome
shares the seven block organization [blocks (B) 1-7; Fig. 1] of
other herpesviruses (30), with subfamily-specific or unique ORFs
present between blocks [interblock regions (IB) a-h; Fig. 1]. ORF
analysis indicates that only 79% of the sequenced 137.5-kb LUR encodes
81 identifiable ORFs, which is likely to be due to our conservative
assignment of ORF positions. Additional potential coding regions are
included as features in the map until experimental verification is
available. The overall LUR CpG dinucleotide observed/expected (O/E)
ratio is 0.75 consistent with a moderate loss of methylated cytosines,
but there is marked regional variation. The lowest CpG O/E ratios
(<0.67) occur in IBa (bp 1-3200), in B5 (68,602-69,405), and IBh
(117,352-137,507). The highest O/E ratios (>0.88) extend from B2 to
B3 (30,701-47,849), in IBe (67,301-68,600), and in B6
(77,251-83,600). Comparison to the KS5 sequence (10) shows a high
sequence conservation between these two strains with only 21 point
mutations over the comparable 20.7-kb region (0.1%). A frameshift
within BC-1 ORF28 (position 49,004) compared with KS5 ORF28 was not
resolvable despite repeated sequencing of KS5 and PCR products
amplified from BC-1. Two additional frameshifts in noncoding regions
(bp 47,862 and 49,338) are also present compared with the KS5 sequence.
Several repeat regions are present in the LUR (Fig. 1). A 143-bp
sequence is repeated within ORF K11 at positions 92,678-92,820 and
92,852-92,994 (waka/jwka). Complex repeats are present in other
regions of the genome: 20- and 30-bp repeats in the region from
24,285-24,902 (frnk), a 13-bp repeat between bases 29,775 and 29,942 (vnct), two separate 23-bp repeat stretches between bases 118,123 and
118,697 (zppa), and 15 different 11- to 16-bp repeats throughout the
region from 124,527 to 126,276 (moi). A complex A+G-rich repeat region
(mdsk) begins at 137,099 and extends into the unsequenced
gap.
Conserved ORFs with homologs found in other herpesviruses are listed in
Table 1, along with their
polarity, map positions, sizes, relatedness to HVS and EBV homologs,
and putative functions. Conserved ORFs coding for presumed viral
structural proteins and enzymes include genes involved in viral DNA
replication [e.g., DNA polymerase (ORF9)], nucleotide synthesis
[e.g., dihydrofolate reductase (DHFR, ORF2), thymidylate synthase (TS,
ORF70)], regulators of gene expression [R transactivator (ORF50)],
and five conserved herpesvirus structural capsid and five glycoprotein
genes.
Table 1.
KSHV ORFs with homology to genes in other
herpesviruses
Proc. Natl. Acad. Sci. USA
Vol. 93,
pp. 14862-14867,
December 1996
Microbiology

,
§,
¶
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES
Library Generation and Screening.
Fig. 1.
Annotated LUR and TR of the KSHV genome. The
orientation of identified ORFs in the LUR are denoted by the direction
of arrows, with HVS homologous ORFs in dark blue and nonhomologous ORFs
in light blue. Seven blocks (numbered) of conserved herpesvirus genes with nonconserved interblock (IB) regions (lettered) are shown under
the kilobase marker; the block numbering scheme differs from the
original description by Chee et al. (30). The
overlapping cosmid (Z prefix) and lambda (L prefix) clones used to map
the KSHV genome are compared with the KS5 lambda phage clone from a KS
lesion and shown below. Features and putative coding regions not
specifically designated are shown above the ORF map. Repeat regions are
shown as white lines (frnk, vnct, waka/jwka, zppa, moi, mdsk).
Putative coding regions and other features (see text) not designated as
ORFs are shown as solid lines.
[View Larger Version of this Image (27K GIF file)]
21) CS+ or
FS dye primer kits (Perkin-Elmer) on Applied Biosystems models 373A or
377 sequenators. Approximately 300 M13 sequences were typically
required to achieve initial coverage for each 10 kb of insert sequence.
Minimum sequence fidelity standards were defined as complete
bidirectional coverage with at least four overlapping sequences at any
given site. For regions with sequence gaps, ambiguities, and
frameshifts, or that did not meet these criteria, primer walking was
done with custom primers (Perkin-Elmer) and dye terminator chemistry
(FS or Ready Reaction kits; Perkin-Elmer). An unsequenced 3-kb region
adjacent to the right end TR sequence in the Z2 cosmid insert could not
be cloned into M13 or Bluescript despite repeated efforts.
Genomic Mapping and Sequence Characteristics.
140.5-kb LUR sequence has 53.5% G+C content and includes
all identified KSHV ORFs. TR regions consist of multiple 801-bp direct
repeat units having 84.5% G+C content (Fig.
2A) with potential packaging and
cleavage sites. Minor sequence variations are present among repeat
units. The first TR unit at the left (Z6) TR junction (205 bp) is
deleted and truncated in BC-1 compared with the prototypical TR unit.
Fig. 2.
(A) Sequence of TR unit demonstrating
its high G+C content. Sequences highly homologous to conserved
herpesvirus pac1 sites are underlined, with lesser
homology sites to specific pac1 and pac2
sequences italicized. (B) Southern blot of DNA from BC-1 (lane 1), BCP-1 (lane 2) and a KS lesion (lane 3) digested with NdeII which cuts once in the TR sequence and probed with
a plasmid containing the TR sequence. The intense hybridization band at 0.8 kb represents multiple copies of the NdeII-digested
single unit TR (C). A schematic representation
(C) of genome structures of KSHV in BCP-1 and BC-1 cell
lines consistent with the data presented in B and
D. Taq I (T) sites flank the TR regions
and NdeII (N) sites are within the TRs. Lowercase tr
refers to the deleted truncated TR unit at the left end of the unique
region. DR represents the duplicated region of the LUR buried within
the TR. (D) Southern blot hybridization with TR probe of DNA
from BC-1 (lane 1), BCP-1 (lane 2), a KS lesion (lane 3), and HBL-6 (lane 4) digested with Taq I, which does not cut in the
TR. Taq I-digested DNA from both BC-1 (lane 1) and HBL-6
(lane 4) show similar TR hybridization patterns, suggesting identical
insertion of a unique sequence into the TR region, which sequencing
studies demonstrate is a duplicated portion of the LUR (see text).
BCP-1 TR hybridization (lane 2) shows laddering consistent with a virus population having variable TR region lengths within this cell line due
to lytic replication. The absence of TR laddering in KS lesion DNA
(lane 3) suggests that a clonal virus population is present in the
tumor.
[View Larger Version of this Image (77K GIF file)]
800-bp signal consistent with the
unit length repeat sequence when digested with enzymes that cut once in
the TR and hybridized to a TR probe (Fig. 2 B and
C). Digestion with enzymes that do not cut in the TR
indicates that the BC-1 strain contains a unique region buried in the TR, flanked by
7-kb and
35-kb TR sequences (Fig. 2
C and D). An identical pattern occurs in HBL-6, a
cell line independently derived from the same tumor as BC-1, suggesting
that this duplication was present in the parental tumor (Fig. 2
C and D). The restriction pattern with
NotI, which also cuts only once within the TR but rarely
within the LUR, suggests that the buried region is at least 33 kb (data
not shown). Partial sequencing of this region demonstrates that it is a
precise genomic duplication of the region beginning at ORF K8 (data not
shown). The LUR is 140.5 kb including the right end unsequenced gap
(<3 kb). The estimated KSHV genomic size in BC-1 and HBL-6 (including
the duplicated region) is
210 kb.

Name
Pol.
Start
Stop
Size
aa
KSHV vs. HVS
KSHV vs. EBV
%
Sim.
% Id.
EBV name
% Sim.
%
Id.
Putative function
% Sim., percent similar; % Id., percent identical; ssDNA,
single-stranded DNA; DHFR, dihydrofolate reductase; FGARAT,
N-formylglycinamide ribotide amidotransforase.
Several genes with homologs to HVS ORFs have unique features. ORF45 has sequence similarity to nuclear and transcription factors (chicken nucleolin and yeast SIR3) and has an extended acidic domain typical for transactivator proteins between amino acids 90 and 115. ORF73 also has an extended acidic domain separated into two regions by a glutamine-rich sequence encoded by the moi repeat. The first region consists almost exclusively of aspartic and glutamic acid residue repeats while the second glutamic acid-rich region has a repeated leucine heptad motif suggestive of a leucine zipper structure. ORF75, a putative tegument protein, has a high level of homology to the purine biosynthetic enzyme of Escherichia coli and Drosophila melanogaster N-formylglycinamide ribotide amidotransferase (FGARAT).
ORFs K3 and K5 are not homologous to HVS genes but are similar to the
major immediate early bovine herpesvirus type 4 (BHV-4) gene IE1 (12 and 13% identity, respectively) (32). While BHV-4 IE1 is spliced, it
is not known if splicing occurs in either KSHV transcript. These genes
have no significant homology to the herpes simplex virus 1 (HSV-1)
0
(which is homologous to BHV-4 IE1), but encode proteins sharing with
the HSV-1 ICP0 protein a cysteine-rich region which may form a zinc
finger motif (32). The hypothetical protein encoded by ORF K5 has a
region homologous to the nuclear localization site present in the late
form of the BHV-4 protein. ORF K8 has a purine binding motif (GLLVTGKS)
in the C terminus of the protein that is similar to a motif present in
the KSHV thymidine kinase (ORF21) (10).
No homologs to HVS ORF1, -3, -5, -12, -13, -14, -15, -51, and -71 were identified in the KSHV LUR sequence. HVS ORF1 codes for a transforming protein, responsible for HVS-induced in vitro lymphocyte transformation (33) and has poor sequence conservation among HVS strains (34, 35). Functional homologs to this gene may be present but were not identifiable by sequence homology. Similarly, no homologs to EBV latency and transformation-associated proteins (EBNA-1, EBNA-2, EBNA-LP, LMP-1, LMP-2, or gp350/220) were found despite some homology to repeat sequences present in these genes. KSHV also does not have a sequence homolog to the BZLF1 EBV transactivator gene.
Several sequences were not given ORF assignments although they have characteristics of expressed genes. The sequence between bp 90,173 and 90,643 shares homology to the precursor of secreted glycoprotein X (gX), encoded by a number of alpha-herpesviruses (pseudorabies, EHV1), and which does not form part of the virion structure. Like its homolog in EHV1, the KSHV form lacks the highly acidic carboxy terminus of the pseudorabies gene.
Two polyadenylylated transcripts expressed at high copy number in BCBL-1 (15) are present at positions 28,661-29,741 (T1.1) in IBb and 118,130-117,436 (T0.7) in IBh. T0.7 encodes a 60-aa peptide (ORF K12) called Kaposin, and T1.1, also referred to as nut-1 (D. Ganem, personal communication), has been speculated to be a U RNA-like transcript (15).
Cell Cycle Regulation and Cell Signaling Protein Homolog Genes.A number of ORFs that are either unique to KSHV or shared only with other gamma-herpesviruses encode homologs to oncoproteins and cell signaling proteins. ORF16, homologous to EBV BHRF-1 and HVS ORF16, encodes a functional Bcl-2-like protein that can inhibit Bax-mediated apoptosis (R. Sarid, T. Sato, and Y.C., unpublished data). ORF72 (11) encodes a functional cyclin D homolog, also found in HVS (37), that can substitute for human cyclin D in phosphorylating the retinoblastoma tumor suppressor protein (38).
KSHV also encodes a functionally active IL-6 (ORF K2) and two
macrophage inflammatory proteins (MIPs) (ORFs K4 and K6), which are not
found in other human herpesviruses (39). The viral (v)IL-6 has 62%
amino acid similarity to the human IL-6 and can substitute for human
IL-6 in preventing mouse myeloma cell apoptosis (39). Both
MIP-like proteins have conserved C-C dimer signatures characteristic of
-chemokines and near sequence identity to human MIP-1
in their
N-terminus regions. MIP-I (ORF K6) can inhibit CCR-5-dependent HIV-1
replication (39). A sequence at bp 22,529-22,185 has low conservation
with MIP-1
(BLASTX poisson, P = 0.0015)
but retains the C-C dimer motif. ORF K9 (vIRF) encodes a hypothetical
449 aa protein with homology to the family of interferon regulatory factors (IRFs) (40). It has 13.4% amino acid identity to human interferon consensus sequence binding protein and partial conservation of the IRF DNA binding domain (39). Three additional nondesignated sequences at bp 88,910-88,410, 90,541-89,600 and 94,127-93,636 also
have low homology to IRF-like proteins (P
0.35). No
conserved interferon consensus sequences were found in this region of
the genome.
Other potential signal transduction homologs, which are also found in other herpesviruses, include a complement-binding protein homolog (v-CBP, ORF4), a neural cell adhesion molecule (NCAM)-like protein (v-adh, ORF K14), and an IL-8 receptor homolog (ORF74). Homologs to ORF4 and -74 are present in other rhadinoviruses and ORF4 is homologous to variola B19L and D12L proteins. ORF K14 (v-adh) is homologous to the rat and human OX-2 membrane antigens, various NCAMs and the poliovirus receptor-related protein PRR1. OX-2 is in turn homologous to ORF U85 of human herpesviruses 6 and 7, but there is no significant homology between the KSHV and beta-herpesvirus OX-2/NCAM homologs. Like other immunoglobulin family adhesion proteins, v-adh has V-like, C-like, transmembrane and cytoplasmic domains, and a potential RGB binding site at residues 268-270. The vIL-8R has a seven transmembrane spanning domain structure characteristic of G-protein coupled chemoattractant receptors (11) which includes the EBV-induced EBI1 protein (41).
The full-length sequence of the KSHV genome in BC-1 cells provides the opportunity to investigate molecular mechanisms of KSHV-associated pathogenesis. The KSHV genome has standard features of rhadinovirus genomes including a single unique coding region flanked by high G+C terminal repeat regions which are the presumed sites for genome circularization. In addition to having 66 conserved herpesvirus genes involved in herpesvirus replication and structure, KSHV is unique in encoding a number of proteins mimicking cell cycle regulatory and signaling proteins.
Our estimated size of the BC-1 derived genome (210 kb including the duplicated portion) is consistent with that found using encapsidated virion DNA (15). Genomic rearrangements are common in cultured herpesviruses (29, 42). However, the genomic duplication present in the BC-1 KSHV probably did not arise during tissue culture passage. TR hybridization studies indicate that this insertion of a duplicated LUR fragment into the BC-1 TR is also present in KSHV from the independently derived HBL-6 cell line (43). It is not known whether this duplication accounts for the inability of KSHV in BC-1 cells to be induced into full lytic replication.
Despite this genomic rearrangement, the KSHV genome is well conserved within coding regions. There is less than 0.1% base pair variation between the BC-1 and the 21-kb KS5 fragment isolated from a KS lesion. Higher levels of variation may be present in strains from other geographic regions or other disease conditions. Within the LUR, synteny to HVS is lost at ORF2 and -70, but there is concordance in all other regions conserved with HVS. Several conserved genes, such as thymidine kinase (10), thymidylate synthase and dihydrofolate reductase [which is present in HVS (27) but not human herpesviruses], may encode proteins that are appropriate targets for existing drugs.
Molecular mimicry by KSHV of cell cycle regulatory and signaling proteins is a prominent feature of the virus. The KSHV genome has genes encoding homologs to cellular complement-binding proteins (ORF4), cytokines (ORFs K2, K4 and K6), a Bcl-2 protein (ORF16), a cytokine transduction pathway protein (K9), an IL-8R-like protein (ORF74), and a D-type cyclin (ORF72). Additional regions potentially coding for proteins with low homology to MIP and IRF-like proteins are also present in the KSHV genome. There is a striking parallel between the cellular homologs encoded by KSHV and cellular genes known to be induced by EBV infection. Cellular cyclin D, CD21/CR2, Bcl-2, an IL-8R-like protein (EBI1), IL-6 and adhesion molecules are upregulated by EBV infection (41, 44-47). This suggests that KSHV modifies the same signaling and regulation pathways as EBV modifies after infection, but does so by introducing exogenous genes from its own genome.
Cellular defense against virus infection commonly involves cell cycle
shutdown, apoptosis (for review, see ref. 48) and elaboration
of cell-mediated immunity (CMI). The KSHV-encoded v-Bcl-2, v-cyclin,
and vIL-6 are active in preventing either apoptosis or cell
cycle shutdown (refs. 38 and 39 and unpublished observation). Functional studies for other gene homologs, such as v-IRF, v-CBP, and
ORF74 are in progress. These may be either agonists or antagonists of
their cellular counterparts. At least one of the
-chemokine homologs, v-MIP-I, prevents CCR5-mediated HIV infection of V-MIP-I transfected cells (39).
-Chemokines are not known to be required for
successful EBV infection of cells although EBV-infected B cells express
higher levels of MIP-1
than normal tonsillar lymphocytes (49). The
autocrine dependence of EBV-infected B cells on small and
uncharacterized protein factors in addition to IL-6 (36) leads to
speculation that
-chemokines may also play a role in the EBV life
cycle.
KSHV has not formally been shown to be a transforming virus and homologs to the major transforming genes of HVS and EBV are not present in the BC-1 strain KSHV. Nonetheless, dysregulation of cell proliferation control caused by the identified KSHV-encoded protooncogenes and cytokines may contribute to neoplastic expansion of virus-infected cells. Preliminary studies suggest that subgenomic KSHV fragments can transform NIH 3T3 cells (R. Sarid, unpublished data). If KSHV replication, like that of EBV, involves recombination of TR units (30), a monomorphic TR hybridization pattern present in a KS lesion would indicate a clonal virus population in the tumor. This is consistent with KS being a true neoplastic proliferation arising from single transformed, KS-infected cell rather than KSHV being a "passenger virus." Identification of KSHV homologs to known oncoproteins and cell proliferation factors in the current study provides evidence that KSHV is likely to be a transforming virus.
J.J.R. and R.A.B. contributed equally to this work.
To whom reprint requests should be addressed.
Abbreviations: KS, Kaposi sarcoma; KSHV, KS-associated
herpesvirus; HVS, herpesvirus saimiri; EBV, Epstein-Barr virus; LUR, long unique region; TR, terminal repeat; ORF, open reading frame; MIP,
macrophage inflammatory peptide; IRF, interferon regulatory factor, IL,
interleukin; IB, interblock region; R, receptor; V, viral.
Data deposition: The sequences reported in this paper have been deposited in the GenBank data base [accession nos. U75698 [GenBank] (long unique unit) and U75699 [GenBank] and U75700 [GenBank] (terminal repeat unit)].
We would like to acknowledge Gifty Asamani and Zhou Ju-Yen for excellent technical assistance, Ai-En Thlick for assistance with the figures, and Xiao-Lu Ye and Peisen Zhang for help with DNA analysis. We also thank Dr. Phil Pellett for critical reading of the manuscript. This work was supported by central funds of the Columbia Genome Center and National Institutes of Health Grant CA67391 awarded to Y.C. and P.S.M.
| 1. | Tappero, J. W., Conant, M. A., Wolfe, S. F. & Berger, T. G. (1993) J. Am. Acad. Dermatol. 28, 371-395 [ISI][Medline] . |
| 2. | Ensoli, B., Barillari, G. & Gallo, R. C. (1992) Immunol. Rev. 127, 147-155 [CrossRef][ISI][Medline] . |
| 3. | Peterman, T. A., Jaffe, H. W. & Beral, V. (1993) AIDS 7, 605-611 [ISI][Medline] . |
| 4. | Chang, Y., Cesarman, E., Pessin, M. S., Lee, F., Culpepper, J., Knowles, D. M. & Moore, P. S. (1994) Science 265, 1865-1869 . |
| 5. | Boshoff, C., Whitby, D., Hatziionnou, T., Fisher, C., van der Walt, J., Hatzakis, A., Weiss, R. & Schulz, T. (1995) Lancet 345, 1043-1044 [ISI][Medline] . |
| 6. | Dupin, N., Grandadam, M., Calvez, V., Gorin, I., Aubin, J. T., Harvard, S., Lamy, F., Leibowitch, M., Huraux, J. M., Escande, J. P. & Agut, H. (1995) Lancet 345, 761-762 [CrossRef][ISI][Medline] . |
| 7. |
Moore, P. S. & Chang, Y.
(1995)
N. Engl. J. Med.
332,
1181-1185
|
| 8. | Schalling, M., Ekman, M., Kaaya, E. E., Linde, A. & Biberfeld, P. (1995) Nat. Med. 1, 707-708 [CrossRef][ISI][Medline] . |
| 9. | Chang, Y., Ziegler, J. L., Wabinga, H., Katongole-Mbidde, E., Boshoff, C., Whitby, D., Schulz, T., Weiss, R. A., Jaffe, H. A. & Moore, P. S. (1996) Arch. Intern. Med. (Moscow) 156, 202-204 . |
| 10. | Moore, P. S., Gao, S.-J., Dominguez, G., Cesarman, E., Lungu, O., Knowles, D. M., Garber, R., McGeoch, D. J., Pellett, P. & Chang, Y. (1996) J. Virol. 70, 549-558 [Abstract]. |
| 11. | Cesarman, E., Nador, R. G., Bai, F., Russo, J., Moore, P. S., Chang, Y. & Knowles, D. M. (1996) J. Virol. 70, 8218-8223 [Abstract]. |
| 12. |
Cesarman, E., Chang, Y., Moore, P. S., Said, J. W. & Knowles, D. M.
(1995)
N. Engl. J. Med.
332,
1186-1191
|
| 13. |
Cesarman, E., Moore, P. S., Rao, P. H., Inghirami, G., Knowles, D. M. & Chang, Y.
(1995)
Blood
86,
2708-2714
|
| 14. | Renne, R., Zhong, W., Herndier, B., McGrath, M., Abbey, N. & Ganem, D. (1996) Nat. Med. 2, 342-346 [CrossRef][ISI][Medline] . |
| 15. |
Zhong, W., Wang, H., Herndier, B. & Ganem, D.
(1996)
Proc. Natl. Acad. Sci. USA
93,
6641-6646
|
| 16. |
Decker, L. L., Shankar, P., Khan, G., Freeman, R. B., Dezube, B. J., Lieberman, J. & Thorley-Lawson, D. A.
(1996)
J. Exp. Med.
184,
283-288
|
| 17. | Gao, S.-J., Kingsley, L., Li, M., Zheng, W., Parravicini, C., Ziegler, J., Newton, R., Rinaldo, C. R., Saah, A., Phair, J., Detels, R., Chang, Y. & Moore, P. S. (1996) Nat. Med. 2, 925-928 [CrossRef][ISI][Medline] . |
| 18. | Sambrook, J., Fritsch, E. F. & Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual (Cold Spring Harbor Lab. Press, Plainview, NY). |
| 19. |
Benton, W. D. & Davis, R. W.
(1977)
Science
196,
180-182
|
| 20. | Hanahan, D. & Meselson, M. (1983) Methods Enzymol. 100, 333-342 [ISI][Medline] . |
| 21. | Feinberg, A. P. & Vogelstein, B. (1983) Anal. Biochem. 132, 6-13 [CrossRef][ISI][Medline] . |
| 22. |
Melton, D. A., Krieg, P. A., Rebagliati, M. R., Maniatis, T., Zinn, K. & Green, M. R.
(1984)
Nucleic Acids Res.
12,
7035-7056
|
| 23. | Deininger, P. L. (1983) Anal. Biochem. 129, 216-223 [CrossRef][ISI][Medline] . |
| 24. | Bankier, A. T., Weston, K. M. & Barrell, B. G. (1987) Methods Enzymol. 155, 51-93 [ISI][Medline] . |
| 25. | Altschul, S. F., Gish, W., Miller, W., Myers, E. W. & Lipman, D. J. (1990) J. Mol. Biol. 215, 403-410 [CrossRef][ISI][Medline] . |
| 26. |
Kozak, M.
(1987)
Nucleic Acids Res.
15,
8125-8148
|
| 27. |
Albrecht, J.-C., Nicholas, J., Biller, D., Cameron, K. R., Biesinger, B., Newman, C., Wittmann, S., Craxton, M. A., Coleman, H., Fleckenstein, B. & Honess, R. W.
(1992)
J. Virol.
66,
5047-5058
|
| 28. | Telford, E. A., Watson, M. S., Aird, H. C., Perry, J. & Davison, A. J. (1995) J. Mol. Biol. 249, 520-528 [CrossRef][ISI][Medline] . |
| 29. | Baer, R., Bankier, A. T., Biggin, P. L., Deininger, P. L., Farrell, P. J., Gibson, T. J., Hatfull, G., Hudson, G. S., Satchwell, S. C., Séguin, C., Tuffnell, P. S. & Barrell, B. G. (1984) Nature (London) 310, 207-211 [CrossRef][Medline] . |
| 30. | Chee, M. S., Bankier, S. B., Bohni, C. M., Brown, R. C., Horsnell, T., Hutchison, C. A., Kouzarides, T., Martignetti, J. A., Preddie, E., Satchwell, S. C., Tomlinson, P., Weston, K. M. & Barrell, B. G. (1990) Curr. Top. Microbiol. Immunol. 154, 125-169 [ISI][Medline] . |
| 31. | Raab-Traub, N. & Flynn, K. (1986) Cell 47, 883-889 [CrossRef][ISI][Medline] . |
| 32. |
van Santen, V.
(1991)
J. Virol.
65,
5211-5224
|
| 33. | Akari, H., Mori, K., Terao, K., Otani, I., Fukasawa, M., Mukai, R. & Yoshikawa, Y. (1996) Virology 218, 382-388 [CrossRef][ISI][Medline] . |
| 34. |
Jung, J. U. & Desrosiers, R. C.
(1991)
J. Virol.
65,
6953-6960
|
| 35. | Jung, J. U. & Desrosiers, R. C. (1995) Mol. Cell. Biol. 15, 6506-6512 [Abstract]. |
| 36. |
Tosato, G., Tanner, G., Jones, K. D., Revel, M. & Pike, S. E.
(1990)
J. Virol.
64,
3033-3041
|
| 37. | Nicholas, J., Cameron, K. R. & Honess, R. W. (1992) Nature (London) 355, 362-365 [CrossRef][Medline] . |
| 38. | Chang, Y., Moore, P. S., Talbot, S. J., Boshoff, C. H., Zarkowska, R., Godden-Kent, D., Peterson, H., Weiss, R. A. & Mittnacht, S. (1996) Nature (London) 382, 410 [CrossRef][Medline] . |
| 39. | Moore, P. S., Boshoff, C., Weiss, R. A. & Chang, Y. (1996) Science, in press. |
| 40. | David, M. (1995) Pharmacol. Ther. 65, 149-161 [CrossRef][Medline] . |
| 41. |
Birkenbach, M., Josefsen, K., Yalamanchili, R., Lenoir, G. & Kieff, E.
(1993)
J. Virol.
67,
2209-2220
|
| 42. | Cha, T.-A., Tom, E., Kemble, G. W., Duke, G. M., Mocarski, E. S. & Spaete, R. R. (1996) J. Virol. 70, 78-83 [Abstract]. |
| 43. | Gaidano, G., Cechova, K., Chang, Y., Moore, P. S., Knowles, D. M. & Dalla-Favera, R. (1996) Leukemia 10, 1237-1240 [Medline] . |
| 44. | Palmero, I., Holder, A., Sinclair, A. J., Dickson, C. & Peters, G. (1993) Oncogene 8, 1049-1054 [ISI][Medline] . |
| 45. |
Finke, J., Fritzen, R., Ternes, P., Trivedi, P., Bross, K. J., Lange, W., Mertelsmann, R. & Dolken, G.
(1992)
Blood
80,
459-469
|
| 46. | Finke, J., Lange, W., Mertelsmann, R. & Dolken, G. (1994) Leuk. Lymphoma 12, 413-419 [ISI][Medline] . |
| 47. |
Jones, K., Rivera, C., Sgadari, C., Franklin, J., Max, E. E., Bhatia, K. & Tosato, G.
(1995)
J. Exp. Med.
182,
1213-1221
|
| 48. | Shen, Y. & Shenk, T. E. (1995) Curr. Opin. Genet. Dev. 5, 105-111 [CrossRef][Medline] . |
| 49. | Harris, P. E., Maffei, A., Liu, Z., Colovai, I., Reed, E. F., Inghirami, G. & Suciu-Foca, N. (1993) J. Immunol. 151, 5975-5983 [Abstract]. |
This article has been cited by other articles in HighWire Press-hosted journals:
![]() |
D. L. Di Bartolo, M. Cannon, Y.-F. Liu, R. Renne, A. Chadburn, C. Boshoff, and E. Cesarman KSHV LANA inhibits TGF-{beta} signaling through epigenetic silencing of the TGF-{beta} type II receptor Blood, May 1, 2008; 111(9): 4731 - 4740. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Majerciak, K. Yamanegi, E. Allemand, M. Kruhlak, A. R. Krainer, and Z.-M. Zheng Kaposi's Sarcoma-Associated Herpesvirus ORF57 Functions as a Viral Splicing Factor and Promotes Expression of Intron-Containing Viral Lytic Genes in Spliceosome-Mediated RNA Splicing J. Virol., March 15, 2008; 82(6): 2792 - 2801. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-J. Zhang, R. S. Bonaparte, D. Patel, D. A. Stein, and P. L. Iversen Blockade of viral interleukin-6 expression of Kaposi's sarcoma-associated herpesvirus Mol. Cancer Ther., March 1, 2008; 7(3): 712 - 720. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Sivakumar, N. Sharma-Walia, H. Raghu, M. V. Veettil, S. Sadagopan, V. Bottero, L. Varga, R. Levine, and B. Chandran Kaposi's Sarcoma-Associated Herpesvirus Induces Sustained Levels of Vascular Endothelial Growth Factors A and C Early during In Vitro Infection of Human Microvascular Dermal Endothelial Cells: Biological Implications J. Virol., February 15, 2008; 82(4): 1759 - 1776. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Sander, A. Konrad, M. Thurau, E. Wies, R. Leubert, E. Kremmer, H. Dinkel, T. Schulz, F. Neipel, and M. Sturzl Intracellular Localization Map of Human Herpesvirus 8 Proteins J. Virol., February 15, 2008; 82(4): 1908 - 1922. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. J. Garrigues, Y. E. Rubinchikova, C. M. DiPersio, and T. M. Rose Integrin {alpha}V 3 Binds to the RGD Motif of Glycoprotein B of Kaposi's Sarcoma-Associated Herpesvirus and Functions as an RGD-Dependent Entry Receptor J. Virol., February 1, 2008; 82(3): 1570 - 1580. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Wies, Y. Mori, A. Hahn, E. Kremmer, M. Sturzl, B. Fleckenstein, and F. Neipel The viral interferon-regulatory factor-3 is required for the survival of KSHV-infected primary effusion lymphoma cells Blood, January 1, 2008; 111(1): 320 - 327. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Z. Gandy, S. D. Linnstaedt, S. Muralidhar, K. A. Cashman, L. J. Rosenthal, and J. L. Casey RNA Editing of the Human Herpesvirus 8 Kaposin Transcript Eliminates Its Transforming Activity and Is Induced during Lytic Replication J. Virol., December 15, 2007; 81(24): 13544 - 13551. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. L. Skalsky, M. A. Samols, K. B. Plaisance, I. W. Boss, A. Riva, M. C. Lopez, H. V. Baker, and R. Renne Kaposi's Sarcoma-Associated Herpesvirus Encodes an Ortholog of miR-155 J. Virol., December 1, 2007; 81(23): 12836 - 12845. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Park, M.-S. Lee, S.-M. Yoo, K. W. Jeong, D. Lee, J. Choe, and T. Seo Identification of the DNA Sequence Interacting with Kaposi's Sarcoma-Associated Herpesvirus Viral Interferon Regulatory Factor 1 J. Virol., November 15, 2007; 81(22): 12680 - 12684. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Feng, J. L. Taylor, P. V. Benos, R. Newton, K. Waddell, S. B. Lucas, Y. Chang, and P. S. Moore Human Transcriptome Subtraction by Using Short Sequence Tags To Search for Tumor Viruses in Conjunctival Carcinoma J. Virol., October 15, 2007; 81(20): 11332 - 11340. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Lan, S. C. Verma, M. Murakami, B. Bajaj, R. Kaul, and E. S. Robertson Kaposi's sarcoma herpesvirus-encoded latency-associated nuclear antigen stabilizes intracellular activated Notch by targeting the Sel10 protein PNAS, October 9, 2007; 104(41): 16287 - 16292. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Cai, M. Murakami, H. Si, and E. S. Robertson A Potential {alpha}-Helix Motif in the Amino Terminus of LANA Encoded by Kaposi's Sarcoma-Associated Herpesvirus Is Critical for Nuclear Accumulation of HIF-1{alpha} in Normoxia J. Virol., October 1, 2007; 81(19): 10413 - 10423. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Xing and E. Kieff Epstein-Barr Virus BHRF1 Micro- and Stable RNAs during Latency III and after Induction of Replication J. Virol., September 15, 2007; 81(18): 9967 - 9975. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. J. Kwun, S. R. da Silva, I. M. Shah, N. Blake, P. S. Moore, and Y. Chang Kaposi's Sarcoma-Associated Herpesvirus Latency-Associated Nuclear Antigen 1 Mimics Epstein-Barr Virus EBNA1 Immune Evasion through Central Repeat Domain Effects on Protein Processing J. Virol., August 1, 2007; 81(15): 8225 - 8235. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. R. Luttichau, A. H. Johnsen, J. Jurlander, M. M. Rosenkilde, and T. W. Schwartz Kaposi Sarcoma-associated Herpes Virus Targets the Lymphotactin Receptor with Both a Broad Spectrum Antagonist vCCL2 and a Highly Selective and Potent Agonist vCCL3 J. Biol. Chem., June 15, 2007; 282(24): 17794 - 17805. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Wang, M. M. Brinkmann, M. Pietrek, M. Ottinger, O. Dittrich-Breiholz, M. Kracht, and T. F. Schulz Functional characterization of the M-type K15-encoded membrane protein of Kaposi's sarcoma-associated herpesvirus J. Gen. Virol., June 1, 2007; 88(6): 1698 - 1707. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. Vart, L. L. Nikitenko, D. Lagos, M. W.B. Trotter, M. Cannon, D. Bourboulia, F. Gratrix, Y. Takeuchi, and C. Boshoff Kaposi's Sarcoma-Associated Herpesvirus-Encoded Interleukin-6 and G-Protein-Coupled Receptor Regulate Angiopoietin-2 Expression in Lymphatic Endothelial Cells Cancer Res., May 1, 2007; 67(9): 4042 - 4051. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Griffiths and A. Whitehouse Herpesvirus Saimiri Episomal Persistence Is Maintained via Interaction between Open Reading Frame 73 and the Cellular Chromosome-Associated Protein MeCP2 J. Virol., April 15, 2007; 81(8): 4021 - 4032. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Zeng, X. Zhang, Z. Huang, L. Cheng, S. Yao, D. Qin, X. Chen, Q. Tang, Z. Lv, L. Zhang, et al. Intracellular Tat of Human Immunodeficiency Virus Type 1 Activates Lytic Cycle Replication of Kaposi's Sarcoma-Associated Herpesvirus: Role of JAK/STAT Signaling J. Virol., March 1, 2007; 81(5): 2401 - 2417. [Abstract] [Full Text] [PDF] |
||||